"I would consider when sleeping to keep one eye open on Multiple Sclerosis"
I totally agree. We're even now have statistically significant mean reduction in Thrombospondin-1 (-49%), and increases in LTBP4 (20.7%), soluble
CXCL16 (29.9%), and VCAM-1 (18.0%) compared to baseline levels (FDR p-value <0.0005) to support ATL1102 in DMD ..
As Mark Diamond once said, "If we show good activity in DMD that could be highly supportive of an MS study." I believe the company will pursue further in this area when the time comes.
"I would consider when sleeping to keep one eye open on Multiple...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $81.13M | |||
| Open | High | Low | Value | Volume |
| 8.9¢ | 9.2¢ | 8.8¢ | $64.35K | 711.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 37301 | 9.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.1¢ | 6019 | 1 |
View Market Depth
| Last trade - 15.46pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
9.2¢ |
Change
0.000 ( 3.37 %) |
||||
| Open | High | Low | Volume | ||
| 8.9¢ | 9.2¢ | 8.8¢ | 138646 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| PER (ASX) Chart |